Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Comprehensive outcome research with safety data and practical protocol references
Inflammation isn't just something to suppress — peptides like ARA-290 and KPV suggest you can reprogram the response entirely.
A plain-English look at the peptides being investigated for inflammation and tissue repair — what the evidence shows, what's still missing, and where the safety line sits.
Detailed compound profiles with mechanisms, safety data, and dosing protocols
Evidence-based supplement stacks designed to support your peptide protocols
Peptide-based gut healing splits across four mechanistically distinct compounds acting on different layers of the gastrointestinal barrier. The animal dossier is extensive; the human evidence is sparse; the regulatory posture is sceptical. An honest map of what is known, what is guessed, and where the practical safety decisions actually are.
BPC-157 drives angiogenesis and tissue repair. Larazotide antagonises zonulin to re-seal tight junctions. KPV suppresses NF-κB-driven inflammation. LL-37 reinforces the antimicrobial and mucus defence. The mechanism map is coherent. The human trial record — Larazotide's discontinued Phase III, BPC-157's three small pilots, the FDA's Category 2 classification — is sobering. Grey-market sourcing, not the peptides themselves, is the dominant source of documented harm.
The Wolverine Stack — how BPC-157 and TB-500 are redefining regenerative medicine for tendon and ligament repair.
A deep dive into the molecular mechanisms, safety protocols, and clinical reality of the two most potent regenerative peptides in orthopedic medicine.
A naturally occurring tripeptide locked inside your collagen that modulates 4,192 human genes, acts as a safe copper chaperone, and signals systemic repair, with plasma levels dropping 60% between ages 20 and 60.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine) is a naturally occurring tripeptide embedded in Type I collagen. Liberated during tissue injury, it acts as a master repair signal modulating 4,192 human genes (roughly one-third of the genome). It drives collagen synthesis, delivers copper safely to enzymes like Superoxide Dismutase via a unique square-planar pyramid configuration, and shows emerging potential in gut barrier repair (SIRT1/STAT3) and COPD reversal (127-gene signature). Plasma levels decline 60% by age 60. Clinical protocols use a biphasic 30-day cycle (1mg escalating to 2mg) with a mandatory 30-day rest. FDA Category 2 restricts legal compounding for systemic use. Contraindicated in active malignancies and Wilson's Disease.
The biochemical cofactors your body needs to support TB-500 therapy.
Evidence-based supplement companion for TB-500 — a synthetic heptapeptide that acts as a molecular GPS for your body's repair crew — directing cell migration, building new blood vessels into injured tissue, and potentially re-activating embryonic healing pathways.
The biochemical cofactors your body needs to support BPC-157 therapy.
Evidence-based supplement companion for BPC-157 — a 15-amino-acid gastric pentadecapeptide that coordinates multi-system repair through angiogenesis, collagen synthesis, and gut-brain axis stabilization.
35+
Articles
18
Categories